引言近年来，局部晚期直肠癌（LARC）治疗策略发展迅速，全程新辅助治疗（total neoadjuvant ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Neoadjuvant systemic treatment (NST) followed by adjuvant treatment with nivolumab and relatlimab offers long-term benefit in adults with stage III/IV resectable melanoma, according to a study ...

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival.

Upper GI cancer treatment depends on a number of factors, and may include treatments such as surgery, chemotherapy, radiation ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Announcing a new article publication for BIO Integration journal. Imbalances in the intestinal microbiome are closely ...

AstraZeneca secures CDSCO approval to import Durvalumab for muscle-invasive bladder cancer treatment in India.

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and ...